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Abstract
Preclinical studies point to a pivotal role of the orexin 1 (OX1) receptor in arousal and fear learning and therefore
suggest the HCRTR1 gene as a prime candidate in panic disorder (PD) with/without agoraphobia (AG), PD/AG
treatment response, and PD/AG-related intermediate phenotypes. Here, a multilevel approach was applied to test the
non-synonymous HCRTR1 C/T Ile408Val gene variant (rs2271933) for association with PD/AG in two independent case-
control samples (total n= 613 cases, 1839 healthy subjects), as an outcome predictor of a six-weeks exposure-based
cognitive behavioral therapy (CBT) in PD/AG patients (n= 189), as well as with respect to agoraphobic cognitions
(ACQ) (n= 483 patients, n= 2382 healthy subjects), fMRI alerting network activation in healthy subjects (n= 94), and a
behavioral avoidance task in PD/AG pre- and post-CBT (n= 271). The HCRTR1 rs2271933 T allele was associated with
PD/AG in both samples independently, and in their meta-analysis (p= 4.2 × 10−7), particularly in the female subsample
(p= 9.8 × 10−9). T allele carriers displayed a signiﬁcantly poorer CBT outcome (e.g., Hamilton anxiety rating scale: p=
7.5 × 10−4). The T allele count was linked to higher ACQ sores in PD/AG and healthy subjects, decreased inferior frontal
gyrus and increased locus coeruleus activation in the alerting network. Finally, the T allele count was associated with
increased pre-CBT exposure avoidance and autonomic arousal as well as decreased post-CBT improvement. In sum,
the present results provide converging evidence for an involvement of HCRTR1 gene variation in the etiology of PD/
AG and PD/AG-related traits as well as treatment response to CBT, supporting future therapeutic approaches targeting
the orexin-related arousal system.
Introduction
The general term orexin (or hypocretin) refers to the
two known hypothalamic neuropeptides comprised in the
orexin class, namely orexin-A and -B (hypocretin 1/2)1.
The orexin system has been implicated in the
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maintenance of arousal, wakefulness, and vigilance as well
as in inﬂuencing motivated behaviors such as emotional
responses, reward seeking and feeding2.
The action of orexin-A and -B is mediated by two
subtypes of G-protein coupled receptors, the orexin 1
(OX1) receptor and the orexin 2 (OX2) receptor
3,4. While
both receptors are co-expressed in the dorsal raphe nuclei
and ventral tegmental area, the OX1 and OX2 receptors
display characteristic anatomical distributions, suggesting
distinct physiological functions based on speciﬁc neuronal
signaling pathways: the OX1 receptor is primarily
expressed in the locus coeruleus (LC), laterodorsal and
pedunculopontine tegmental nucleus, while the OX2
receptor is located in the arcuate and tuberomammillary
nucleus5. In addition, site-speciﬁc exclusive expression of
the OX1 receptor has been reported in the cingulate
cortex, CA1/2 region of the hippocampus, bed nucleus of
the stria terminalis and amygdala5. Nonetheless, it should
be kept in mind that gene expression information is
ultimately limited by mRNA detection and antibody
staining sensitivity and speciﬁcity.
Besides this abundance of the OX1 receptor in circuity
engaged during fear6, a pivotal role of the OX1 receptor in
the pathogenesis of hyperarousal- and panic-related
anxiety has been suggested by both preclinical and clin-
ical studies:7 In a rodent model, the orexin system has
been shown to modulate the formation and expression of
fear memory via noradrenergic neurons in the LC
expressing the OX1 receptor, with Hcrtr1(−/−) mice
displaying impaired freezing responses in both cued and
contextual fear-conditioning paradigms8. Additionally,
blocking orexin activity in the noradrenergic LC has been
reported to reduce fear learning in a comparable fear
conditioning paradigm9. Accordingly, selective OX1
receptor antagonism has been shown to attenuate
anxiety-related behavior in the open ﬁeld and social
interaction test and to reduce neural responses in the
central nucleus of the amygdala, bed nucleus of the stria
terminalis, periaqueductal gray and in the rostroven-
trolateral medulla10. Correspondingly, pre-treatment with
an OX1 receptor antagonist attenuated sodium lactate-
induced anxiety-related behavior, locomotor, and cardi-
oexcitatory responses and even worked in a panic-prone
strain of rats in a comparable fashion to alprazolam11. In a
similar vein, pre-treatment with an OX1 receptor
antagonist attenuated hypercapnia-induced panic-related
behavior and hypertension12. Furthermore, systemic OX1
receptor blockage and site-speciﬁc blockage in the
amygdala have been demonstrated to support the
extinction of aversive memories, facilitating the con-
solidation of cue- and context-dependent fear extinction,
potentially via increased infralimbic medial-prefrontal
cortex activity13. Translating preclinical research to
potential clinical applications, human subjects reporting
panic-associated symptoms have been found to display
elevated qualitative levels of orexin in the cerebrospinal
ﬂuid (CSF) compared to subjects without panic-like
anxiety11. Additionally, chronic treatment with sertra-
line, a ﬁrst-line anti-panic drug, has been observed to
reduce orexin levels in the CSF of depressed patients14.
In sum, given the large body of evidence supporting a
key role of particularly the OX1 receptor in hyperarousal-
and panic-related fear reactions, the gene coding for the
OX1 receptor (HCRTR1; chromosome 1p35.2) — con-
taining a potentially functionally relevant C/T single
nucleotide polymorphism (SNP) (rs2271933) in exon 7
leading to an amino acid exchange from isoleucine to
valine (Ile408Val)15–18 — is suggested as a prime candi-
date regarding these phenotypes. Thus, in a multilevel
approach, we examined the association between HCRTR1
rs2271933 genotype and panic disorder in two indepen-
dent samples of patients with panic disorder (PD) with
and without agoraphobia (AG) and healthy controls.
Within these samples, we explored the possibility of
predicting treatment response according to clinical out-
come measures based on HCRTR1 rs2271933 genotype in
a controlled and randomized exposure-based cognitive-
behavioral therapy (CBT) trial. Subsequently, we tested
for an association between HCRTR1 rs2271933 genotype
and agoraphobic cognitions as measured by the Agor-
aphobic Cognitions Questionnaire (ACQ) in both PD/AG
patients and healthy subjects. Activation in the alerting
network as elicited by the attention network task (ANT) —
comprising the LC as well as right lateralized fronto-parietal
regions particularly important for anxiety-related arousal
regulation19,20 — was investigated dependent on HCRTR1
rs2271933 genotype and in correlation with dimensional
measures of agoraphobic cognitions in an extended sample
of healthy probands. Finally, HCRTR1 rs2271933 effects on
behavioral avoidance and psychophysiological autonomic
arousal during a behavioral avoidance task (BAT) were
assessed in PD/AG patients. It was hypothesized that
HCRTR1 genotype-driven dysfunctional panic-related cog-
nitions and behaviors as well as an oversensitivity of neural
network and psychophysiological responses related to
arousal and alerting might provide a pathomechanistic
framework for an increased vulnerability to PD/AG as well
as an impaired response to CBT.
Materials and methods
For detailed information on samples, genotyping, CBT
design, functional magnetic resonance imaging (fMRI)
paradigm, BAT, and all statistical analyses refer to the
Supplementary Methods.
Samples
The discovery sample (‘MAC sample’) for the associa-
tion study comprised a subsample of the two waves of the
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‘Mechanism of Action in CBT’ study (MAC) funded by
the German Federal Ministry of Education and Research
(BMBF)21. It consisted of 483 participants of Caucasian
origin with available blood samples and primary PD/AG
(age= 35.1 ± 10.7 years, 341 females [70.6%], 24 cases
without comorbid agoraphobia [5.0%], 127 cases with
comorbid depression [26.3%], all cases free of psycho-
tropic medication; for additional demographic informa-
tion including PD/AG age of onset and therapeutic
history see Supplementary Table 1). For categorical
associations, an optimal 1:3 matching with healthy con-
trols (HC) was performed (“optimal matching” as imple-
mented in the R package MatchIt aims to minimize the
global distance measure by matching samples with the
smallest average absolute distance across all matched
pairs, minimizing the distance between each pair22,23)
based on age and sex against an available dataset of
screened healthy controls recruited from the SFBTRR-58
subproject Z02 recruitment waves 1 and 2 (n= 2382; age
= 25.2 ± 5.8 years, 1486 females [62.4%]). Matching was
limited to a 1:3 ratio due to the availability of healthy
female control samples (see below)24. In addition, the total
sample of MAC PD/AG patients and SFBTRR-58 Z02
healthy controls had been characterized for scores on the
German version of the Agoraphobic Cognitions Ques-
tionnaire (ACQ)25.
The replication sample (‘Münster sample’) consisted of
130 patients with primary PD/AG (age= 35.7 ± 11.1
years, 84 females [64.6%], 40 cases without comorbid
agoraphobia [30.8%], 46 cases with comorbid depression
[35.4%]) and 130 healthy controls (age= 35.8 ± 10.1 years)
recruited at the Department of Psychiatry and Psy-
chotherapy, University of Münster, Germany, supple-
mented with healthy controls recruited from the SFBTRR-
58 subproject Z02 recruitment waves 1 and 2 and not
used in the matching process for the discovery sample, in
order to again reach a PD/AG:HC ratio of 1:3. Study
inclusion criteria were comparable between the discovery
and replication samples and based on DSM-IV criteria
(see Supplementary Methods).
Patients and healthy controls gave full written informed
consent; the studies were in agreement with the
Declaration of Helsinki and approved by the respective
local ethics committees.
Cognitive-behavioral psychotherapy (CBT)
Within the MAC study, patients underwent CBT ses-
sions following a manualized structure and administered
twice weekly, with a total of 12 sessions26. A subsample of
patients was available for genetic analyses (n= 189; age =
35.4 ± 11.0 years, 139 females [73.5%]).
Primary outcome measures investigated in the MAC
study were the Hamilton Anxiety Rating Scale (HAM-A),
the Clinical Global Impressions Scale (CGI), the Panic and
Agoraphobia Scale (PAS), the number of panic attacks in
the week prior to assessment and the Mobility Inventory
for Agoraphobia Avoidance “Alone” Scale (MI), all of
which were assessed at baseline and post CBT26.
Functional MRI
A total of 94 healthy subjects of Caucasian descent
performed the fMRI task (age= 28.5 ± 8.9 years, 63
females [67.0%], 44 samples drawn from the SFBTRR-58
subproject Z02 recruitment waves 1 and 2 and 50 samples
additionally recruited at the Department of Psychiatry,
Psychosomatics, and Psychotherapy, University of Würz-
burg, Germany). Analyses focused on neural activity of
the alerting network as evaluated via the Attentional
Network Task (ANT) capturing alerting, orienting and
executive functions. The paradigm and data acquisition
have been published previously (see Supplementary
Methods)19.
Behavioral avoidance task (BAT)
A subsample of the ‘MAC sample’ during recruitment
wave 1 underwent the behavioral avoidance task27,28. The
protocol for the BAT comprised of an exposure to a dark,
small and closed test chamber which patients would ﬁrst
sit in front of with the door open for 10min (‘anticipation
phase’) before being locked in for a maximum of 10 min
(‘exposure phase’), followed by the ‘recovery phase’, again,
in front of the open door for 8 min. Avoidance behavior
and psychophysiological measures were ascertained in all
phases (see Supplementary Methods; for additional pre-
treatment heart rate and pre- and post-treatment sub-
jective fear readouts refer to the Supplementary Results
and Discussion). Patients were explicitly allowed to ter-
minate the BAT protocol at any time. Dependent on their
behavior during the task, patients were categorized into
one of three groups: ‘passive avoidance’ (no attempt of
exposure in the BAT chamber), ‘active avoidance’ (ﬂight
during the 10 min period of exposure) and ‘no avoidance’
(no attempt of escape during the exposure). After com-
pletion of each phase, patients were instructed to rate
their subjective experience of fear on a visual analogue
scale of 1 to 10. Mean heart rates during the three phases
were recorded via a continuous electrocardiogram.
Full HCRTR1 rs2271933 genotype and BAT data was
available for 271 PD/AG patients pre-CBT (age= 36.1 ±
10.9 years, 202 females [74.5%]) and for 183 patients post-
CBT, excluding those randomized to a wait-list-control
group (n= 49), treatment drop-outs (n= 33) and those
who failed to repeat the BAT after therapy (n= 6).
Genotyping
All samples were genotyped for the HCRTR1 rs2271933
using a PCR-restriction-fragment-length-polymorphism
(RFLP) assay (see Supplementary Methods).
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Results
Categorical diagnosis of panic disorder with and without
comorbid agoraphobia
HCRTR1 rs2271933 allele and genotype frequencies and
full test statistics, p-values, odds ratios (OR) and 95%
conﬁdence intervals (CI) for the discovery sample (MAC
study) and the replication sample (Münster sample) are
given in Table 1.
In the MAC discovery sample, rs2271933 T allele
loading was signiﬁcantly associated with PD/AG in the
Cochran–Armitage test and the allelic Pearson’s χ²-test.
Furthermore, the genotype model Pearson’s χ²-test sup-
ported a recessive effect of the T allele in PD/AG (TT vs
CC/CT). Stratiﬁcation by sex revealed a predominantly
female association effect.
The association between the rs2271933 T allele and PD/
AG was successfully validated in the Münster replication
sample via the Cochran–Armitage test and Pearson’s χ²-
tests for the allelic and recessive genotype models. Again,
the genetic association was predominately driven by the
female subsample of the Münster sample.
Meta-analytical combination of the total discovery and
replication samples (613 PD/AG patients, 1839 controls)
in a ﬁxed-effects model resulted in a signiﬁcantly increased
OR for both, the recessive (OR 1.82 [95%CI= 1.83–2.41],
Z= 4.18, p= 2.9 × 10−5) and the allelic model (OR 1.51
[95%CI= 1.29–1.77], Z= 5.06, p= 4.2 × 10−7) (Fig. 1).
Further meta-analyses conﬁrmed the increased PD/AG
OR in females only for the recessive (OR 2.59 [95%CI=
1.81–3.69], Z= 5.25, p= 2.0 × 10−4) and allelic model (OR
1.78 [95%CI= 1.46–2.17], Z= 5.73, p= 9.8 × 10−9).
CBT treatment response in panic disorder with and
without comorbid agoraphobia
In the MAC PD/AG patient subsample undergoing CBT
(HCRTR1 rs2271933 genotype distribution: CC= 58, CT
= 78, TT= 53), TT genotype carriers displayed a sig-
niﬁcantly decreased treatment response as assessed via
HAM-A scores (TT vs CC and TT vs CT), CGI scores (TT
vs CC; trend towards signiﬁcance for TT vs CT) and PAS
scores (TT vs CC; trend towards signiﬁcance for TT vs
CT). Furthermore, in T allele homozygotes a trend
towards a signiﬁcantly diminished treatment response on
the MI was discerned when compared to CT hetero-
zygotes. Applying a recessive model (TT vs CC/CT) the
reduced treatment response effects in T allele homo-
zygotes remained signiﬁcant for the HAM-A (p= 1.5 ×
10−3), CGI (p= 0.031) and PAS (p= 0.044) scores. For full
test statistics, p-values, ORs and 95% CIs refer to Table 2.
Dimensional anxiety traits in panic disorder with and
without comorbid agoraphobia and in healthy controls
Within the total MAC PD/AG patient sample, T allele
loading was signiﬁcantly associated with increased ACQ
scores (by 1.90 points per T allele, 95%CI: 0.76–3.04
points; allelic model, p= 0.027). When evaluating the
effect of the rs2271933 T allele on ACQ scores within the
sample of 2382 healthy subjects, T allele loading was again
signiﬁcantly associated with an increased ACQ score (by
0.50 points per T allele, 95%CI 0.35–0.65 points; allelic
model, p= 0.014).
Alerting network in healthy controls
In the sample of healthy probands performing the fMRI
Attention Network Task (HCRTR1 rs2271933 genotype
distribution: CC= 23, CT= 50, TT= 21), two signiﬁcant
clusters of neural activation in the alerting condition were
detected when applying a gene dosage analysis (Fig. 2a):
One cluster within the right inferior frontal gyrus (IFG, x
= 34, y= 44, z=−10) with decreasing activation asso-
ciated with increased T allele counts (Z= 3.1, p= 0.041,
FDR-corrected at the voxel level) and one cluster within
the bilateral locus coeruleus (LC, x=−14, y=−16, z=
−2) with increasing activation associated with increased T
allele counts (Z= 3.2, p= 0.031, FDR-corrected at the
voxel level).
In order to address the relation between neural activa-
tion of the alerting system, rs2271933 T allele count and
dimensional anxiety traits (ACQ), interaction analyses
were performed. Neural activation in the LC cluster sig-
niﬁcantly correlated with increased ACQ scores in TT
genotype carriers and decreased ACQ scores in CC gen-
otype carriers (Fig. 2b) (TT > CC/CT: Z= 3.5, p= 0.032;
TT > CC: Z= 3.6, p= 0.028; TT > CT: Z= 1.5, p= 0.210).
A negative correlation between ACQ scores and right IFG
activation in TT genotype carriers reached trend-wise
signiﬁcance (TT < CC/CT: Z= 2.1, p= 0.084; TT < CC: Z
= 1.9, p= 0.089; TT < CT: Z= 0.01, p= 0.981).
There was no genotype effect on accuracy and reaction
time on the behavioral level. To assess the relation
between ACQ scores and behavioral parameters, partial
correlations were performed using sex as nuisance vari-
able: ACQ scores did not signiﬁcantly inﬂuence beha-
vioral performance (Raccuracy= 0.039, p= 0.714; Rreaction
time=−0.055, p= 0.600, Ralerting= 0.075, p= 0.480).
Behavioral avoidance task (BAT) in panic disorder with and
without comorbid agoraphobia
Pre-treatment assessment (HCRTR1 rs2271933 geno-
type distribution: CC= 79, CT= 120, TT= 72): During
the BAT, frequency of avoidance behavior was sig-
niﬁcantly more pronounced along with an increasing
number of rs2271933 T alleles (categorical BAT analysis;
passive avoidance by genotype: CC= 2 [2.5%], CT= 15
[12.5%], TT= 12 [16.7%]; active avoidance by genotype:
CC= 19 [24.1%], CT= 21 [17.5%], TT= 15 [20.8%]; no
avoidance by genotype: CC= 58 [73.4%], CT= 84
[70.0%], TT= 45 [62.5%]; linear-to-linear trend: χ²(1)=
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5.172, p= 0.023). Concordantly, mean duration of toler-
ated BAT exposure trended towards a signiﬁcant decrease
with increasing T allele loading (dimensional BAT ana-
lysis; linear trend p= 0.073; Fig. 3a).
In those patients entering the test chamber, the mean
heart rate during BAT anticipation did not signiﬁcantly
differ between patients showing active avoidance vs no
avoidance during BAT exposure (Behavior F(1,186)=
0.338, p= 0.562). Also, no genotype effect was observed
during the anticipation phase (Genotype F(2,186)= 1.718,
p= 0.182; Genotype × Behavior F(2,186)= 2.476, p=
0.087). However, while the initial heart rate increase
during BAT exposure did not differ between genotype
groups in active avoiders (F(2,42)= 0.615, p= 0.546), the
heart rate response decreased with increasing number of
T alleles in non-avoiding patients (linear trend: p=
7.7·10−3; Fig. 3b).
Post-treatment assessment (HCRTR1 rs2271933 geno-
type distribution: CC= 57, CT= 75, TT= 51): In patients
showing active or passive avoidance behavior during the
BAT assessment prior to therapy, the increase of the
mean duration of tolerated BAT exposure from pre- to
post-assessment diminished with an increasing number of
rs2271933 T alleles (linear trend p= 0.043; Fig. 3c).
Accordingly, the pre- to post-assessment reduction of
the initial heart rate response from anticipation to expo-
sure phase attenuated with an increasing number of
rs2271933 T alleles (linear trend p= 6.0 × 10−3; Fig. 3d)
irrespective of whether patients showed active avoidance
or not during the BAT pre-treatment assessment (Gen-
otype × Behavior F(2,119)= 0.294, p= 0.746).
Discussion
Our data demonstrate an association between the
HCRTR1 rs2271933 T allele and PD/AG in a Caucasian
population, including a successful replication and meta-
analysis. The HCRTR1 rs2271933 driven non-
synonymous Ile408Val substitution resides in the recep-
tor’s C-terminus and is therefore likely to be part of a
domain involved in protein-protein interaction, but as of
yet, it remains to be experimentally tested, whether the
SNP affects expression levels, effector coupling or
dimerization of the OX1 receptor
29. Based on the above
mentioned ﬁndings the T allele — presently discerned to
mediate hyperarousal- and/or panic-related anxiety
behavior — is hypothesized to enhance OX1 receptor
signaling (e.g., on the expression level, or due to reduced
cycling/desensitization) and thereby to increase the
orexinergic tone in key brain areas of the arousal/alerting
system. Interestingly, the genetic association was mainly
driven by the female subsamples of the present samples, a
phenomenon already observed in other neuropeptide-
and monoamine/catecholamine-related polymorphisms
implicated in PD/AG pathology30,31. Indeed, sexuallyTa
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dimorphic expression of orexin and the orexin receptors
in the CNS has been described in mice32. Furthermore, it
has been shown that restraint stress-induced HPA-axis
activation and cognitive impairments via increased glu-
cocorticoid receptor-dependent orexin expression occur
exclusively in female rats and can be prevented by che-
mogenetic inhibition of hypothalamic orexinergic neu-
rons, pointing to a sex-speciﬁc role of orexins and their
receptors in stress susceptibility33. The only other study
evaluating orexin receptor polymorphisms in PD/AG
failed to show genetic association for HCRTR1 rs2271933,
but rather reported a signiﬁcant ﬁnding for the HCRTR2
rs2653349 A allele, again predominantly in the female
subsample15. It should be noted, however, that in this
previous study PD/AG sample size was limited, controls
were not screened for PD/AG and no independent
replication was provided.
Moreover, the HCRTR1 rs2271933 T allele was found to
confer signiﬁcantly poorer outcomes on clinical assess-
ments (HAM-A, CGI) and a self-report measurement
(PAS) following exposure-based CBT. Given that changes
in vigilance for threat information have been demon-
strated to precede and predict clinical changes in
exposure-based CBT for PD/AG34, an altered orexinergic
tonus differentially driven by rs2271933 genotype and
affecting arousal/alerting processes might inﬂuence CBT
outcome in PD/AG. The present ﬁnding extends the
emerging body of evidence for biomarkers of psy-
chotherapy response prediction in PD/AG, so far mainly
focusing on genetic variations related to serotonergic and
monoaminergic neurotransmission such as the mono-
amine oxidase A (MAOA) upstream variable number of
tandem repeats (uVNTR) SNP35, to the arousal-related
orexin system.
Fig. 1 Forest plots of HCRTR1 rs2271933 meta-analyses of association with PD/AG. PD/AG= panic disorder with and without agoraphobia;
MAC= discovery sample; Münster= replication sample. FE= ﬁxed-effects. Values in brackets represent 95% conﬁdence intervals of odds ratios
Gottschalk et al. Translational Psychiatry            (2019) 9:75 Page 6 of 13    75 
Ta
b
le
2
A
ss
oc
ia
ti
on
st
ud
ie
s
of
H
C
R
TR
1
rs
22
71
93
3
an
d
C
B
T
tr
ea
tm
en
t
re
sp
on
se
B
as
el
in
e
Po
st
C
B
T
Ef
fe
ct
si
ze
C
T
vs
C
C
Ef
fe
ct
si
ze
d
iff
er
en
ce
TT
vs
C
C
Ef
fe
ct
si
ze
d
iff
er
en
ce
TT
vs
C
T
Ef
fe
ct
si
ze
d
iff
er
en
ce
O
ut
co
m
e
G
en
ot
yp
e
N
M
ea
n
SD
M
ea
n
SD
d
95
%
C
I
p-
va
lu
e
d
95
%
C
I
p-
va
lu
e
d
95
%
C
I
p-
va
lu
e
d
95
%
C
I
p-
va
lu
e
H
A
M
-A
α
C
C
58
25
.2
5.
5
12
.1
6.
9
−
2.
5
−
2.
9
−
2.
1
4.
83
·1
0−
18
C
T
77
24
.1
5.
2
11
.4
7.
0
−
2.
6
−
2.
8
−
2.
3
8.
33
·1
0−
30
TT
53
23
.2
4.
9
14
.8
8.
2
−
1.
7
−
2.
1
−
1.
3
1.
56
·1
0−
12
−
0.
1
−
0.
5
0.
4
0.
76
4
0.
6
0.
1
1.
1
5.
6·
10
−
3
0.
7
0.
2
1.
1
1.
3·
10
−
3
C
G
Iα
C
C
58
5.
2
0.
7
3.
2
1.
1
−
2.
9
−
3.
3
−
2.
4
4.
85
·1
0−
18
C
T
77
5.
2
0.
8
3.
4
1.
0
−
2.
5
−
2.
9
−
2.
2
1.
77
·1
0−
22
TT
53
5.
3
0.
7
3.
8
1.
1
−
2.
2
−
2.
6
−
1.
8
2.
08
·1
0−
14
0.
3
−
0.
3
0.
8
0.
15
0
0.
7
0.
1
1.
3
8.
7·
10
−
3
0.
4
−
0.
1
1.
0
0.
06
2+
PA
Sα
C
C
58
27
.2
10
.0
12
.4
8.
0
−
1.
5
−
1.
8
−
1.
3
5.
92
·1
0−
17
C
T
75
27
.1
10
.0
14
.1
9.
6
−
1.
3
−
1.
6
−
1.
1
4.
33
·1
0−
16
TT
53
28
.0
10
.0
16
.2
9.
8
−
1.
2
−
1.
5
−
0.
9
8.
59
·1
0−
12
0.
1
−
0.
2
0.
4
0.
19
5
0.
3
0.
0
0.
7
0.
01
7
0.
2
−
0.
1
0.
5
0.
07
7+
Pa
ni
c
at
ta
ck
s
C
C
58
2.
6
2.
4
1.
1
1.
8
−
0.
4
−
0.
7
−
0.
2
1.
84
·1
0−
03
C
T
78
2.
6
2.
4
1.
0
1.
4
−
0.
5
−
0.
8
−
0.
3
3.
17
·1
0−
05
TT
53
2.
6
2.
3
1.
5
2.
0
−
0.
3
−
0.
6
0.
0
2.
54
·1
0−
02
0.
1
−
0.
1
0.
3
0.
12
9
0.
1
−
0.
1
0.
3
0.
10
1
0.
0
−
0.
1
0.
2
0.
39
6
M
I
C
C
49
2.
9
0.
9
1.
9
0.
8
−
1.
1
−
1.
4
−
0.
8
1.
09
·1
0−
10
C
T
66
2.
9
0.
7
1.
8
0.
7
−
1.
3
−
1.
5
−
1.
1
1.
33
·1
0−
18
TT
53
3.
0
0.
9
2.
0
0.
9
−
1.
1
−
1.
4
−
0.
9
1.
23
·1
0−
12
−
0.
2
−
0.
5
0.
1
0.
26
4
0.
1
−
0.
2
0.
4
0.
34
7
0.
2
−
0.
1
0.
5
0.
06
0+
Tr
ea
tm
en
t
ef
fe
ct
si
ze
di
sp
la
ye
d
as
w
ith
in
-
an
d
be
tw
ee
n-
gr
ou
ps
C
oh
en
’s
d
ba
se
d
on
pr
e/
po
st
C
BT
sc
or
e
m
ea
ns
an
d
ba
se
lin
e
st
an
da
rd
de
vi
at
io
n.
Ef
fe
ct
si
ze
di
ff
er
en
ce
s
ba
se
d
on
ro
bu
st
lin
ea
r
re
gr
es
si
on
w
er
e
co
rr
ec
te
d
fo
r
ou
tc
om
e’
s
ba
se
lin
e
va
lu
es
Si
gn
iﬁ
ca
nt
ef
fe
ct
si
ze
di
ff
er
en
ce
s
hi
gh
lig
ht
ed
in
bo
ld
(p
-v
al
ue
<
0.
05
)
N
ot
e
th
at
th
e
nu
m
be
r
of
pa
ni
c
at
ta
ck
s
in
th
e
pr
ev
io
us
w
ee
k
is
al
so
a
su
b-
ite
m
of
th
e
in
te
gr
at
ed
PA
S
sc
or
e
d
C
oh
en
’s
d
ef
fe
ct
si
ze
,H
A
M
-A
H
am
ilt
on
A
nx
ie
ty
Ra
tin
g
Sc
al
e,
CG
I
C
lin
ic
al
G
lo
ba
l
Im
pr
es
si
on
s
Sc
al
e,
PA
S
Pa
ni
c
an
d
A
go
ra
ph
ob
ia
Sc
al
e,
M
I
M
ob
ili
ty
In
ve
nt
or
y,
CI
co
nﬁ
de
nc
e
in
te
rv
al
+
Tr
en
d
- w
is
e
si
gn
iﬁ
ca
nc
e
at
p-
va
lu
e
<
0.
1
α
Si
gn
iﬁ
ca
nt
ef
fe
ct
si
ze
di
ff
er
en
ce
in
a
re
ce
ss
iv
e
de
si
gn
(T
T
vs
C
C
/C
T)
w
ith
re
du
ce
d
tr
ea
tm
en
t
re
sp
on
se
in
T
al
le
le
ho
m
oz
yg
ot
es
(f
or
fu
ll
st
at
is
tic
al
in
fo
rm
at
io
n
se
e
Su
pp
le
m
en
ta
ry
Ta
bl
e
2)
Gottschalk et al. Translational Psychiatry            (2019) 9:75 Page 7 of 13    75 
Fig. 2 (See legend on next page.)
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In the attempt to explore intermediate phenotypic levels
potentially contributing to the observed genotype effects,
the HCRTR1 rs2271933 T allele count was found to be
associated with increased agoraphobic cognitions (ACQ)
scores within the MAC PD/AG patient sample and in a
large sample of psychiatrically healthy subjects. It has
already been shown that increased ACQ scores correlate
directly with increased bodily sensations in feared situa-
tions in anxiety disorder patients and in psychiatrically
healthy controls36. Accordingly, elevated ACQ scores
prior to a CO2 challenge predicted the intensity of
frightening cognitions after inhalation, both in a PD/AG
and a healthy control sample37, thus providing a cognitive
link between arousal-related interoceptive sensations and
PD/AG risk. Also, the presently observed therapygenetic
effect might in part be explained by the fact that the
HCRTR1 rs2271933 T allele predicted increased ACQ
scores, given that catastrophic misinterpretations during a
12-week CBT program have previously been shown to
impair therapeutic success38. In sum, the HCRTR1
rs2271933 T allele might confer an increased proneness to
PD/AG-related catastrophizing thought patterns and
thereby increased PD/AG risk as well as treatment failure.
On a neural level, we observed a signiﬁcant effect of
HCRTR1 rs2271933 genotype on alerting network acti-
vation in healthy subjects, with an increased T allele count
associated with decreased neural response in the right
inferior frontal gyrus (IFG) and an increased response in
the locus coeruleus (LC). Remarkably, LC activation var-
ied positively in function of the ACQ in T allele homo-
zygotes, signifying that a higher ACQ score was linked to
a stronger neural bottom-up processing of internal sti-
muli. At the same time, reduced activation in the IFG, a
region which has been hypothesized to represent the
modulation of warning signals on the level of alertness,
might indicate an impaired top-down inhibition of the
subcortical alerting network39. Orexin has been reported
to activate noradrenergic LC neurons and thereby
heightens arousal40. Notably, in terms of fear conditioning
Hcrtr1 knockout mice displayed impaired freezing
responses and reduced neural activation of the lateral
amygdala, which could be rescued by adeno-associated
viral-mediated restoration of Hcrtr1 expression in the
LC8. Local microinjections of an OX1 receptor antagonist
and subsequent optogenetic speciﬁc stimulation of orexin
ﬁbers in the LC further validated the importance of OX1
receptor-controlled norepinephrinergic LC neurons in the
formation of fear memories9. Additionally, the informa-
tion that hypercapnia leads to increased brainstem acti-
vation in PD/AG patients compared to healthy controls41,
and the positive correlation between LC activation and
ACQ scores in TT genotype carriers, advocate for an
increased risk of developing PD/AG due to a combination
of elevated attention to autonomic bodily functions and
increased somatic arousal due to dysfunctional cortical
attentional networks20,42. Moreover, overactivation of the
LC-amygdala circuit has been linked to increased fear
generalization, which was reversible under OX1 receptor
antagonist treatment43. Since individuals with higher trait
anxiety and amygdala hyperresponsivity have been proven
to exhibit an increased resistance to fear extinction44,
overactivation of the LC in alerting conditions presently
identiﬁed in HCRTR1 rs2271933 T allele homozygotes,
may have signiﬁcantly impaired CBT efﬁciency of
exposure-based extinction learning, as observed in the
treatment response analysis. In sum, the present results
propose a HCRTR1 genotype by phenotype interaction in
terms of an imbalance between frontal top-down and
brain stem bottom-up control in the alerting network,
reﬂecting a putative neuronal model of hyperarousal in
the perception and processing of fear-related bodily
symptoms with relevance to PD/AG pathology as well as
therapy resistance due to abnormal stimulus general-
ization and extinction.
Finally, the HCRTR1 rs2271933 T allele was associated
with increased rates of avoidance behavior and a
decreased capacity to endure psychophysiological activa-
tion in PD/AG patients during a fear-provoking beha-
vioral avoidance test (BAT). Surprisingly, T allele loading
was associated with decreased physiological fear reactivity
to BAT exposure as indicated by the measured heart rate
responses, however, only in BAT non-avoiding but not in
BAT escaping patients. In T allele homozygotes displaying
no active avoidance, no substantial fear increase from
anticipation to exposure was observed. Thus, if the
patients’ arousal system is activated, T allele carriers
might be signiﬁcantly more likely to avoid the fear-
inducing situation, manifesting in escape from the phobic
environment, resulting in more frequent avoidance
behavior and, in turn, lower levels of autonomic fear in
Fig. 2 HCRTR1 rs2271933 genotypes and the alerting system. a Left: Signiﬁcant HCRTR1 rs2271933 gene-dose effect clusters in the alerting
system are overlaid on a single subject T1 anatomical image. Right and bottom: Bar plots represent the HCRTR1 rs2271933 genotype-dose effect in
terms of contrast estimates at the local maxima. b Effects of Agoraphobic Cognitions Questionnaire (ACQ) scores on the alerting network. Top:
Activation clusters rendered on a single subject brain surface. Bottom: Correlations of ACQ scores with locus coeruleus (LC) activation. In HCRTR1
rs2271933 T allele homozygotes, ACQ scores correlated positively with LC neural activity, while there was a negative correlation in C allele
homozygotes (see Results)
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non-avoiding subjects as compared to non-risk-allele
carriers. Our results are in line with current learning
theories in PD/AG, stating that chances of experiencing
another panic attack are heightened once they have been
associated with internal cues of elevated arousal. This
could explain why T allele carriers would most likely
choose to avoid phobic exposure in general and thus are
more prone to develop PD/AG from an initial panic
attack45. Additionally, we found an increased main-
tenance of avoidance behavior during the BAT after CBT
treatment with an increasing number of rs2271933 T
alleles that went along with a lack of a reduction of
physiological fear reactivity from pre- to post-treatment
assessment. Reduced tolerance of fear activation during
phobic exposure — as displayed by T allele carriers —
could possibly be detrimental for safety learning and thus
impede successful fear extinction, as observed in the
treatment response analysis46. In line with this hypothesis,
agoraphobic avoidance was the most consistent predictor
of decreased improvement in CBT for PD/AG in a recent
systematic literature review47. Taken together, the present
data support the notion, that the HCRTR1 rs2271933 T
allele might confer a genetic risk of decreased resilience to
phobic exposure in PD/AG resulting in pronounced
avoidance behavior.
The present results should be considered in the light of
some limitations. Besides the necessity to replicate our
ﬁndings in even larger samples, particularly when
Fig. 3 HCRTR1 rs2271933 T allele loading and behavioral avoidance task (BAT) outcomes. a T allele loading vs pre-treatment (pre-CBT)
duration of exposure (s). b T allele loading vs pre-treatment initial heart rate response (Δbpm) during exposure, i.e., increase from last minute of
anticipation to ﬁrst minute of exposure, in non-avoiding patients. c T allele loading vs the pre- to post-treatment difference in tolerated duration of
exposure (Δs). d T allele loading vs the pre- to post-treatment difference of the initial heart rate response (Δbpm) during exposure. All values are
presented as means ± standard error (SE)
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stratifying for sex, several factors not accounted for and
thus potentially confounding the present results such as
possible moderation effects by childhood trauma and
recent life events should be controlled for in future stu-
dies. Given that the healthy controls were younger than
the PD/AG patient populations, despite optimal matching
of the available samples, we cannot exclude a potential
bias in the results given the possibility that they might
develop a PD/AG later in life. Along these lines, epige-
netic mechanisms like DNA methylation mediating
environmental inﬂuences and governing gene function
remain to be addressed48. The decision to investigate only
one SNP in the HCRTR1 gene was based on its likely
functional relevance and due to it having been investi-
gated in the majority of association studies on HCRTR1
gene variation in neuropsychiatric phenotypes15–18.
However, in order to capture the entire HCRTR1 gene
information and to exclude potential effects of population
stratiﬁcation, a tagging SNP approach would have to be
applied. Additionally, it should be noted that SNPs in
linkage disequilibrium with rs2271933 could causally
drive the reported ﬁndings, yet this would optimally
require whole genome sequencing data to be ruled out
entirely. Future studies are warranted to experimentally
delineate the presently only assumed functionality of
HCRTR1 rs2271933 and its interaction with other estab-
lished psychiatric candidate gene variants. Particularly,
the interaction of HCRTR1 and HCRTR2 gene variation
remains to be elucidated given preclinical evidence for a
bi-directional control of anxiety via orexin receptors49.
In conclusion, we have gathered converging evidence
for a both patho-genetic and therapy-genetic role of the
HCRTR1 rs2271933 T allele in PD/AG. In synopsis with
translational preclinical studies, the present ﬁndings
suggest a potential value of OX1 receptor antagonists as a
novel treatment strategy in arousal- and panic-related
anxiety10–13. Also, applying a personalized treatment
approach, HCRTR1 gene variation, along with physiolo-
gical, neurocircuit, behavioral and self-report measures,
might aid in predicting treatment response and allow for
tailoring therapeutic interventions to the individual
patient’s risk factor constellation50,51.
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